Live Breaking News & Updates on கட்டுப்படுத்தப்படுகிறது இரட்டை குருட்டு கட்டம்

Share this article
Share this article
RARITAN, N.J., Feb. 8, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA
® and ZYTIGA
® plus prednisone (control arm).
1 Results will be featured in an oral presentation at the American Society of Clinical Oncology s Genitourinary (ASCO GU) Cancers Symposium, taking place virtually February 11-13, 2021 (Abstract #9; Oral Abstract Session: Prostate Cancer, February 11, 12:45 PM-2:00 PM EST). ....

United States , Jennifer Mcintyre , Christopher Delorefice , Obrian Kenney , None Of The Janssen Pharmaceutical Companies , National Comprehensive Cancer Network Inc , World Health Organization , Drug Administration , American Urological Association , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Laboratory Abnormalities , Exchange Commission , Prostate Cancer Panel , Companies Of Johnson , European Commission On , American Society , Clinical Oncology , Cancers Symposium , Oral Abstract Session , Prostate Cancer , Practice Guidelines , Castration Resistant Prostate Cancer , Evidence Level Grade , National Comprehensive Cancer Network ,